{ "run": { "id": "cmnqyvgze00hmp6580cy5zpmr", "region": "BR", "assetId": "cmnqyvgyt00hip658e56pzxni", "ticker": "FLRY3", "snapshotId": "cmnqyvgz300hkp6580lykc1ot", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T04:18:19.704Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnqyvgz300hkp6580lykc1ot", "assetId": "cmnqyvgyt00hip658e56pzxni", "asOf": "2026-04-08T21:30:33.000Z", "snapshot": { "asOf": "2026-04-08T21:30:33.000Z", "quote": { "asOf": "2026-04-08T21:30:33.000Z", "open": 16.55, "price": 16.13, "dayLow": 16.13, "volume": 4375800, "dayHigh": 16.55, "currency": "BRL", "prevClose": 16.19, "week52Low": 11.77, "week52High": 18.1 }, "fundamentals": { "pe": 14.34415295686972, "beta": 0, "epsTTM": 1.1245965, "fcfTTM": 852166000, "growth": { "epsYoy": 6.8011503, "revenueYoy": 3.507699 }, "sector": "Saúde", "margins": { "net": 0.071964525, "gross": 0.26607028, "operating": 0.14728273 }, "website": "https://www.grupofleury.com.br", "industry": "Serviços Médicos Hospitalares", "pegRatio": 0, "ebitdaTTM": 2121459000, "forwardPe": 0, "marketCap": 8690293618, "totalCash": 2162391000, "totalDebt": 6429368000, "debtEquity": 1.2615836, "quickRatio": 1.8884093, "revenueTTM": 8291182000, "companyName": "Fleury SA", "priceToBook": 0, "currentRatio": 1.9688758, "dividendYield": 0.09578582269063857, "returnOnAssets": 0.04513232, "returnOnEquity": 0.11707999, "analystOpinions": 0, "businessSummary": "A Fleury S.A., listada na B3 sob o ticker FLRY3, é uma companhia brasileira de medicina diagnóstica e serviços de saúde fundada em 1926. A empresa atua com exames laboratoriais, diagnósticos por imagem, medicina preventiva e soluções integradas para pessoas e empresas.\n\nA operação é estruturada em múltiplas marcas e diferentes faixas de posicionamento, com presença em várias regiões do país. O portfólio inclui unidades de atendimento, operação hospitalar, coleta domiciliar e serviços digitais de apoio à jornada de cuidado.\n\nA estratégia de crescimento combina expansão orgânica, aquisições e integração de plataformas de diagnóstico e cuidado ambulatorial. O grupo também vem ampliando atuação em atenção primária, especialidades e serviços de coordenação de saúde.\n\nNo mercado brasileiro, a Fleury está entre os principais grupos privados de diagnóstico, com escala relevante em exames de alta…", "enterpriseValue": 4266977000, "analystTargetLow": 0, "analystTargetHigh": 0, "analystTargetMean": 0, "fullTimeEmployees": 10000, "sharesOutstanding": 0, "enterpriseToEbitda": 2.0113409, "analystTargetMedian": 0, "enterpriseToRevenue": 0.5146404, "operatingCashflowTTM": 2133775000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T04:18:19.695Z" }, "results": [ { "id": "cmnqyvgzg00hop658hiudwr9u", "runId": "cmnqyvgze00hmp6580cy5zpmr", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"FLRY3\",\"currency\":\"BRL\",\"current_price\":16.13,\"target_price_6m\":17.0,\"target_price_12m\":17.80,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Attractive ~9.6% dividend yield provides strong total return floor\",\"PE of 14.3x is reasonable for a defensive healthcare diagnostics leader\",\"FCF yield near 10% supports dividends and deleveraging capacity\",\"Modest revenue growth of 3.5% YoY limits re-rating catalyst near-term\",\"Debt/equity of 1.26x warrants monitoring but manageable with strong cash flow\"],\"key_drivers\":[{\"driver\":\"High dividend yield (~9.6%) attracting income-focused investors\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Defensive healthcare sector positioning amid macro uncertainty\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Strong operating cash flow (BRL 2.1B) supporting capital allocation\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Low single-digit revenue growth limiting upside momentum\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Elevated total debt (BRL 6.4B) increasing financial risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"M&A integration and synergy realization from acquisitions\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net margin at 7.2% with potential for operational leverage\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Brazilian interest rate environment affecting cost of debt\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Expansion into primary care and ambulatory services\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"High Selic rates increasing cost of debt and pressuring net income\",\"Competitive pressure from hospital chains integrating diagnostics in-house\",\"Regulatory changes in Brazilian private healthcare reimbursement\",\"Integration risk from acquisitive growth strategy diluting returns\",\"FX and macro deterioration reducing consumer healthcare spending\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.155,\"wacc\":0.13,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":13.50,\"prob\":0.2,\"notes\":\"PE compresses to ~11.5x on macro deterioration and margin erosion from high debt costs.\"},\"base\":{\"target_price\":17.80,\"prob\":0.55,\"notes\":\"Steady EPS growth of ~7%, slight PE re-rating to ~15x with continued strong dividends.\"},\"bull\":{\"target_price\":21.00,\"prob\":0.25,\"notes\":\"Margin expansion via M&A synergies and organic growth acceleration drive PE to ~17x.\"}},\"method_notes\":\"Earnings-power valuation anchored on TTM EPS of BRL 1.12 growing ~7% to ~BRL 1.20 in 12M. Base PE target of ~15x yields BRL 17.80. EV metrics in snapshot appear inconsistent (EV=4.27B vs implied ~12.96B from mktcap+debt-cash); used PE-based approach. High dividend yield (~9.6%) adds to total return but price target reflects capital appreciation only. ~10.4% expected price return supports BUY. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "ai-equity-research-v1", "risks": [ "High Selic rates increasing cost of debt and pressuring net income", "Competitive pressure from hospital chains integrating diagnostics in-house", "Regulatory changes in Brazilian private healthcare reimbursement", "Integration risk from acquisitive growth strategy diluting returns", "FX and macro deterioration reducing consumer healthcare spending" ], "ticker": "FLRY3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Steady EPS growth of ~7%, slight PE re-rating to ~15x with continued strong dividends.", "target_price": 17.8 }, "bear": { "prob": 0.2, "notes": "PE compresses to ~11.5x on macro deterioration and margin erosion from high debt costs.", "target_price": 13.5 }, "bull": { "prob": 0.25, "notes": "Margin expansion via M&A synergies and organic growth acceleration drive PE to ~17x.", "target_price": 21 } }, "confidence": 0.62, "assumptions": { "wacc": 0.13, "revenue_cagr_3y": 0.06, "terminal_multiple": 14.5, "ebit_margin_target": 0.155 }, "key_drivers": [ { "driver": "High dividend yield (~9.6%) attracting income-focused investors", "impact": "HIGH", "direction": "POS" }, { "driver": "Defensive healthcare sector positioning amid macro uncertainty", "impact": "HIGH", "direction": "POS" }, { "driver": "Strong operating cash flow (BRL 2.1B) supporting capital allocation", "impact": "HIGH", "direction": "POS" }, { "driver": "Low single-digit revenue growth limiting upside momentum", "impact": "MED", "direction": "NEG" }, { "driver": "Elevated total debt (BRL 6.4B) increasing financial risk", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration and synergy realization from acquisitions", "impact": "MED", "direction": "POS" }, { "driver": "Net margin at 7.2% with potential for operational leverage", "impact": "MED", "direction": "POS" }, { "driver": "Brazilian interest rate environment affecting cost of debt", "impact": "MED", "direction": "NEG" }, { "driver": "Expansion into primary care and ambulatory services", "impact": "LOW", "direction": "POS" } ], "method_notes": "Earnings-power valuation anchored on TTM EPS of BRL 1.12 growing ~7% to ~BRL 1.20 in 12M. Base PE target of ~15x yields BRL 17.80. EV metrics in snapshot appear inconsistent (EV=4.27B vs implied ~12.96B from mktcap+debt-cash); used PE-based approach. High dividend yield (~9.6%) adds to total return but price target reflects capital appreciation only. ~10.4% expected price return supports BUY. Not investment advice.", "current_price": 16.13, "recommendation": "BUY", "thesis_bullets": [ "Attractive ~9.6% dividend yield provides strong total return floor", "PE of 14.3x is reasonable for a defensive healthcare diagnostics leader", "FCF yield near 10% supports dividends and deleveraging capacity", "Modest revenue growth of 3.5% YoY limits re-rating catalyst near-term", "Debt/equity of 1.26x warrants monitoring but manageable with strong cash flow" ], "target_price_6m": 17, "target_price_12m": 17.8 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 34697, "createdAt": "2026-04-09T04:18:19.704Z", "usage": { "inputTokens": 3750, "outputTokens": 1645, "costUsd": 0.059875 } }, { "id": "cmnqyvgzg00hrp6584d6ssvoy", "runId": "cmnqyvgze00hmp6580cy5zpmr", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research_Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"FLRY3\",\n \"currency\": \"BRL\",\n \"current_price\": 16.13,\n \"target_price_6m\": 18.62,\n \"target_price_12m\": 19.25,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Moderate revenue growth driven by healthcare demand.\",\n \"Strong market presence in Brazilian diagnostics sector.\",\n \"Operational efficiency leading to margin improvement.\",\n \"High dividend yield offers income and value support.\",\n \"Valuation appears reasonable with upside potential.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Healthcare demand growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operational cost control\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory environment changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic conditions\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Service expansion and innovation\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt and interest rate exposure\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Technological adoption in diagnostics\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Regulatory changes impacting pricing and operations.\",\n \"Economic slowdown reducing healthcare spending.\",\n \"Intensified competition from other diagnostic providers.\",\n \"Currency volatility affecting financials.\",\n \"Execution risks in strategic initiatives.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.15,\n \"wacc\": 0.1,\n \"terminal_multiple\": 5.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 14.0, \"prob\": 0.2, \"notes\": \"Slower growth and margin pressure.\" },\n \"base\": { \"target_price\": 19.25, \"prob\": 0.6, \"notes\": \"Steady execution and market conditions.\" },\n \"bull\": { \"target_price\": 22.0, \"prob\": 0.2, \"notes\": \"Accelerated growth and efficiency gains.\" }\n },\n \"method_notes\": \"Valuation based on forward P/E with growth assumptions. BUY due to ~19% upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI_Equity_Research_Model", "risks": [ "Regulatory changes impacting pricing and operations.", "Economic slowdown reducing healthcare spending.", "Intensified competition from other diagnostic providers.", "Currency volatility affecting financials.", "Execution risks in strategic initiatives." ], "ticker": "FLRY3", "currency": "BRL", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution and market conditions.", "target_price": 19.25 }, "bear": { "prob": 0.2, "notes": "Slower growth and margin pressure.", "target_price": 14 }, "bull": { "prob": 0.2, "notes": "Accelerated growth and efficiency gains.", "target_price": 22 } }, "confidence": 0.6, "assumptions": { "wacc": 0.1, "revenue_cagr_3y": 0.04, "terminal_multiple": 5, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Healthcare demand growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operational cost control", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory environment changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic conditions", "impact": "MED", "direction": "NEG" }, { "driver": "Service expansion and innovation", "impact": "MED", "direction": "POS" }, { "driver": "Debt and interest rate exposure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Technological adoption in diagnostics", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on forward P/E with growth assumptions. BUY due to ~19% upside. Not investment advice.", "current_price": 16.13, "recommendation": "BUY", "thesis_bullets": [ "Moderate revenue growth driven by healthcare demand.", "Strong market presence in Brazilian diagnostics sector.", "Operational efficiency leading to margin improvement.", "High dividend yield offers income and value support.", "Valuation appears reasonable with upside potential." ], "target_price_6m": 18.62, "target_price_12m": 19.25 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 342, "createdAt": "2026-04-09T04:18:19.704Z", "usage": { "inputTokens": 2221, "outputTokens": 4486, "costUsd": 0.002506 } }, { "id": "cmnqyvgzg00hpp6582ddwplo0", "runId": "cmnqyvgze00hmp6580cy5zpmr", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"FLRY3\",\n \"currency\": \"BRL\",\n \"current_price\": 16.13,\n \"target_price_6m\": 17.20,\n \"target_price_12m\": 18.50,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Defensive healthcare profile with resilient diagnostic demand and strong brand equity.\",\n \"High dividend yield of 9.6% provides a solid total return floor for investors.\",\n \"Hermes Pardini integration synergies continue to support margin expansion and EPS growth.\",\n \"Moderate top-line growth of 3.5% reflects a mature market but stable pricing power.\",\n \"Leverage remains manageable, though high interest rates pressure net income margins.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Hermes Pardini Synergies\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Selic Interest Rate\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Health Insurer (Operadoras) Default/Renegotiation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"B2B Reference Lab Growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Dividend Payout Ratio\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New Patient Service Centers (PSC) Openings\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Increased bargaining power and delayed payments from health insurance companies.\",\n \"Higher-for-longer Selic rates increasing financial expenses on 6.4B BRL debt.\",\n \"Integration execution risks and potential failure to capture projected M&A synergies.\",\n \"Regulatory changes in the supplementary healthcare market.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.155,\n \"wacc\": 0.115,\n \"terminal_multiple\": 13.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 14.0,\n \"prob\": 0.25,\n \"notes\": \"Margin compression from insurer pushback and higher debt servicing costs.\"\n },\n \"base\": {\n \"target_price\": 18.5,\n \"prob\": 0.55,\n \"notes\": \"Steady synergy realization, 5% revenue CAGR, and stable 15.5% EBIT margins.\"\n },\n \"bull\": {\n \"target_price\": 21.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated B2B growth and Selic rate cuts drive multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF (WACC 11.5%, 3% terminal growth) and target P/E of 13.5x. The 14.7% upside supports a BUY rating, bolstered by a ~9.6% dividend yield. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Equity Analyst", "risks": [ "Increased bargaining power and delayed payments from health insurance companies.", "Higher-for-longer Selic rates increasing financial expenses on 6.4B BRL debt.", "Integration execution risks and potential failure to capture projected M&A synergies.", "Regulatory changes in the supplementary healthcare market." ], "ticker": "FLRY3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Steady synergy realization, 5% revenue CAGR, and stable 15.5% EBIT margins.", "target_price": 18.5 }, "bear": { "prob": 0.25, "notes": "Margin compression from insurer pushback and higher debt servicing costs.", "target_price": 14 }, "bull": { "prob": 0.2, "notes": "Accelerated B2B growth and Selic rate cuts drive multiple expansion.", "target_price": 21 } }, "confidence": 0.7, "assumptions": { "wacc": 0.115, "revenue_cagr_3y": 0.05, "terminal_multiple": 13.5, "ebit_margin_target": 0.155 }, "key_drivers": [ { "driver": "Hermes Pardini Synergies", "impact": "HIGH", "direction": "POS" }, { "driver": "Selic Interest Rate", "impact": "HIGH", "direction": "NEG" }, { "driver": "Health Insurer (Operadoras) Default/Renegotiation", "impact": "MED", "direction": "NEG" }, { "driver": "B2B Reference Lab Growth", "impact": "MED", "direction": "POS" }, { "driver": "Dividend Payout Ratio", "impact": "MED", "direction": "POS" }, { "driver": "New Patient Service Centers (PSC) Openings", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF (WACC 11.5%, 3% terminal growth) and target P/E of 13.5x. The 14.7% upside supports a BUY rating, bolstered by a ~9.6% dividend yield. Not investment advice.", "current_price": 16.13, "recommendation": "BUY", "thesis_bullets": [ "Defensive healthcare profile with resilient diagnostic demand and strong brand equity.", "High dividend yield of 9.6% provides a solid total return floor for investors.", "Hermes Pardini integration synergies continue to support margin expansion and EPS growth.", "Moderate top-line growth of 3.5% reflects a mature market but stable pricing power.", "Leverage remains manageable, though high interest rates pressure net income margins." ], "target_price_6m": 17.2, "target_price_12m": 18.5 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24986, "createdAt": "2026-04-09T04:18:19.704Z", "usage": { "inputTokens": 2441, "outputTokens": 862, "costUsd": 0.015226 } }, { "id": "cmnqyvgzg00hnp6581zsti9wg", "runId": "cmnqyvgze00hmp6580cy5zpmr", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"gpt-5-equity-analyst\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"FLRY3\",\"currency\":\"BRL\",\"current_price\":16.13,\"target_price_6m\":16.6,\"target_price_12m\":17,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Diagnostics demand is defensive, supporting steady cash generation through cycles.\",\"Operating margins remain healthy, but topline growth is only low-single-digit.\",\"High dividend yield underpins total return, though not enough for clear re-rating.\",\"Leverage is manageable with liquidity, yet debt constrains upside in higher rates.\",\"Valuation looks roughly fair absent faster ambulatory-care expansion or stronger earnings growth.\"],\"key_drivers\":[{\"driver\":\"Defensive diagnostics demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Premium brand pricing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Strong cash conversion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Dividend support\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low revenue growth\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Debt load vs rates\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Ambulatory care cross-sell\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Competitive pricing pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Reimbursement and pricing pressure\",\"Labor and medical supply inflation\",\"Execution risk in care platform expansion\",\"Higher interest rates pressure equity value\"],\"assumptions\":{\"revenue_cagr_3y\":6,\"ebit_margin_target\":15,\"wacc\":12.5,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":14.2,\"prob\":0.3,\"notes\":\"Growth stalls and rates stay high, limiting re-rating.\"},\"base\":{\"target_price\":17,\"prob\":0.5,\"notes\":\"Steady volumes, stable margins and modest earnings growth.\"},\"bull\":{\"target_price\":19.5,\"prob\":0.2,\"notes\":\"Better cross-sell and faster outpatient expansion lift earnings.\"}},\"method_notes\":\"Base case uses normalized earnings power and cash generation with a market multiple anchor. HOLD fits only ~5% 12M price upside and mixed evidence. Snapshot quote fields were kept authoritative; snapshot EV appears inconsistent with debt/cash, so valuation leaned on P/E and margins instead. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "gpt-5-equity-analyst", "risks": [ "Reimbursement and pricing pressure", "Labor and medical supply inflation", "Execution risk in care platform expansion", "Higher interest rates pressure equity value" ], "ticker": "FLRY3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady volumes, stable margins and modest earnings growth.", "target_price": 17 }, "bear": { "prob": 0.3, "notes": "Growth stalls and rates stay high, limiting re-rating.", "target_price": 14.2 }, "bull": { "prob": 0.2, "notes": "Better cross-sell and faster outpatient expansion lift earnings.", "target_price": 19.5 } }, "confidence": 0.58, "assumptions": { "wacc": 12.5, "revenue_cagr_3y": 6, "terminal_multiple": 14.5, "ebit_margin_target": 15 }, "key_drivers": [ { "driver": "Defensive diagnostics demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Premium brand pricing", "impact": "MED", "direction": "POS" }, { "driver": "Strong cash conversion", "impact": "HIGH", "direction": "POS" }, { "driver": "Dividend support", "impact": "MED", "direction": "POS" }, { "driver": "Low revenue growth", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt load vs rates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Ambulatory care cross-sell", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pricing pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Base case uses normalized earnings power and cash generation with a market multiple anchor. HOLD fits only ~5% 12M price upside and mixed evidence. Snapshot quote fields were kept authoritative; snapshot EV appears inconsistent with debt/cash, so valuation leaned on P/E and margins instead. No sell-side targets used; not investment advice.", "current_price": 16.13, "recommendation": "HOLD", "thesis_bullets": [ "Diagnostics demand is defensive, supporting steady cash generation through cycles.", "Operating margins remain healthy, but topline growth is only low-single-digit.", "High dividend yield underpins total return, though not enough for clear re-rating.", "Leverage is manageable with liquidity, yet debt constrains upside in higher rates.", "Valuation looks roughly fair absent faster ambulatory-care expansion or stronger earnings growth." ], "target_price_6m": 16.6, "target_price_12m": 17 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_052fc6d74921b2270069d72a567fc481948028781f05f27d5d", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 30999, "createdAt": "2026-04-09T04:18:19.704Z", "usage": { "inputTokens": 2454, "outputTokens": 2075, "costUsd": 0.033344 } }, { "id": "cmnqyvgzg00hqp6584mylmmzg", "runId": "cmnqyvgze00hmp6580cy5zpmr", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"FLRY3\",\n \"currency\": \"BRL\",\n \"current_price\": 16.13,\n \"target_price_6m\": 17.5,\n \"target_price_12m\": 19.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Established leader in Brazilian diagnostics\",\n \"High 9.6% dividend yield supports returns\",\n \"Growth via acquisitions and preventive care\",\n \"Stable margins amid efficiency initiatives\",\n \"Balanced by competition and debt leverage\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Brazil healthcare demand growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Test volume and preventive services\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A integration and scale benefits\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competition from rival labs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"High debt and interest costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Macroeconomic conditions in Brazil\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Intensifying competitive pressure\",\n \"Economic slowdown curbing volumes\",\n \"M&A execution and integration issues\",\n \"Rising rates increasing debt burden\",\n \"Regulatory changes in healthcare\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 6.5,\n \"ebit_margin_target\": 15.0,\n \"wacc\": 10.5,\n \"terminal_multiple\": 13.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 14.2,\n \"prob\": 0.3,\n \"notes\": \"Weak economy and margin compression.\"\n },\n \"base\": {\n \"target_price\": 19.0,\n \"prob\": 0.5,\n \"notes\": \"Steady execution on growth and efficiency.\"\n },\n \"bull\": {\n \"target_price\": 23.5,\n \"prob\": 0.2,\n \"notes\": \"Accelerated demand and successful M&A.\"\n }\n },\n \"method_notes\": \"DCF with 3y explicit forecast using revenue CAGR, EBIT margin, WACC and terminal multiple. 18% 12M upside supports BUY per rubric. Consensus not used numerically. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Equity Research Model", "risks": [ "Intensifying competitive pressure", "Economic slowdown curbing volumes", "M&A execution and integration issues", "Rising rates increasing debt burden", "Regulatory changes in healthcare" ], "ticker": "FLRY3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on growth and efficiency.", "target_price": 19 }, "bear": { "prob": 0.3, "notes": "Weak economy and margin compression.", "target_price": 14.2 }, "bull": { "prob": 0.2, "notes": "Accelerated demand and successful M&A.", "target_price": 23.5 } }, "confidence": 0.62, "assumptions": { "wacc": 10.5, "revenue_cagr_3y": 6.5, "terminal_multiple": 13.5, "ebit_margin_target": 15 }, "key_drivers": [ { "driver": "Brazil healthcare demand growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Test volume and preventive services", "impact": "HIGH", "direction": "POS" }, { "driver": "M&A integration and scale benefits", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Competition from rival labs", "impact": "MED", "direction": "NEG" }, { "driver": "High debt and interest costs", "impact": "MED", "direction": "NEG" }, { "driver": "Macroeconomic conditions in Brazil", "impact": "HIGH", "direction": "POS" } ], "method_notes": "DCF with 3y explicit forecast using revenue CAGR, EBIT margin, WACC and terminal multiple. 18% 12M upside supports BUY per rubric. Consensus not used numerically. Not investment advice.", "current_price": 16.13, "recommendation": "BUY", "thesis_bullets": [ "Established leader in Brazilian diagnostics", "High 9.6% dividend yield supports returns", "Growth via acquisitions and preventive care", "Stable margins amid efficiency initiatives", "Balanced by competition and debt leverage" ], "target_price_6m": 17.5, "target_price_12m": 19 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "161d802c-eaba-918e-925e-d0111e8e987b", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20450, "createdAt": "2026-04-09T04:18:19.704Z", "usage": { "inputTokens": 2792, "outputTokens": 3286, "costUsd": 0.057666 } } ] } }